Market Insights
The report titled “Chronic Myeloid Leukemia (CML) Treatment Market: Growth, Future Prospects, and Competitive Analysis, 2016–2023” offers strategic insights into the overall chronic myeloid leukemia (CML) treatment market, along with the market size and estimates for the duration 2013–2023. The said research study covers an in-depth analysis of multiple market segments based on types of drugs and different geographies. According to Leukemia CARE, chronic myeloid leukemia (CML) is a form of blood cancer that affects the white blood cells known as myeloid cells. It is a slowly progressing form of leukemia. In CML, the bone marrow carries out an overproduction of white cells, or granulocytes, which steadily crowd the bone marrow, ultimately interfering with normal blood cell production. There are no specific signs or symptoms that would allow a diagnosis of CML to be made. The most common signs and symptoms are caused by the bone marrow not being able to produce enough normal blood cells. CML accounts for 15% of all leukemias in adults, and approximately 8,220 new cases of CML will be diagnosed in 2016, with an estimated 1,070 deaths. The age-adjusted incidence is 1.6 per 100,000 population.
Market experts suggest that CML is not considered curable with standard treatments, with the possible exception of stem cell transplants in a small number of younger and/or fitter patients. A new class of drugs called tyrosine kinases (TKIs) or BCR-ABL inhibitors has transformed the treatment of CML. Currently, existing BCR-ABL inhibitors form the stronghold of CML treatment, which comprises first-generation imatinib and more effective second-generation BCR-ABL inhibitors nilotinib and dasatinib, with ponatinib and bosutinib having been recently approved for market inclusion. A few published reports exhibit that nilotinib and dasatinib have higher efficacy than imatinib in first-line chronic-phase CML (CML-CP), allowing more patients to get effective results with comparatively more rapid responses related to enhanced results.
The geographical segmentation comprised regions such as North America, Europe, Asia-Pacific, Latin America & the Middle East, and Africa. Each geographical region is further split to provide market revenue for select countries such as the U.S., Canada, the U.K., Germany, China, Japan, Brazil, and GCC countries. The market size and forecast for these segments during 2013–2023 and their CAGRs for the period 2016–2023 are provided in this report.
The chronic myeloid leukemia (CML) market is observed as the most diversified and competitive market, comprising a large number of players. The market is dominated by several players, depending on their major competencies. The key players in this market are Novartis AG, Bristol-Myers Squibb, Teva Pharmaceuticals Industries Ltd., ARIAD Pharmaceuticals, Inc., Pfizer, Inc., Hospira, Inc., Prism Pharmaceuticals, Incyte Corporation, Bio-Path Holdings, Strange Pharma SA, Otsuka Pharmaceutical Co., Ltd., and others.
Based on the type of treatment, the global chronic myeloid leukemia (CML) treatment market is segmented as follows:
- Targeted Therapy
- Imatinib
- Dasatinib
- Nilotinib
- Bosutinib
- Ponatinib
- Chemotherapy
- Radiation Therapy
- Splenectomy
- stem cell transplant
According to the American Cancer Society, chronic myeloid leukemia (CML) cells contain an oncogene, BCR-ABL, that isn’t found in normal cells. These genes possess the ability to make a protein, BCR-ABL, which causes CML cells to grow and reproduce at an abnormally quick rate. BCR-ABL is a type of protein known as a tyrosine kinase. Drugs known as tyrosine kinase inhibitors (TKIs) that target BCR-ABL are the standard treatment for CML. Medical practitioners suggest that the BCR-ABL protein inhibits cell apoptosis and DNA repair, leading to genomic instability and further genetic abnormalities. Oncologists also suggest that earlier stem cell therapy was commonly used to treat CML before the launch of modern targeted therapy drugs like imatinib.
The drugs that were available earlier did not work very well, and less than half of patients survived more than five years after diagnosis. Now, targeted drugs like imatinib are the standard treatment, and transplants are being used less often. In 2015, targeted therapy accounted for the largest share of the CML treatment market due to its high efficiency, increased life expectancy, insurance coverage in developed and developing countries, and rising patient awareness related to targeted therapy. A stem cell transplant may be an option for some younger patients or patients who are intolerant to or resistant to TKIs, providing them with a better chance of a cure.
For the purpose of this study, the global chronic myeloid leukemia (CML) market is categorized into three segments:
- North America
- Europe
- Asia Pacific
- Latin America (LATAM)
- Middle East and Africa (MEA)
In the base year of 2015, North America was observed as the leading geographical region in the chronic myeloid leukemia treatment market due to the rising diagnosis rate of chronic myeloid leukemia, the market entry of novel targeted drug therapies, and an organized medical insurance environment. The American Cancer Society estimates that in 2016, about 8,220 new cases will be diagnosed with CML (4,610 in men and 3,610 in women), and about 1,070 people will die of CML (570 men and 500 women). According to a research study published in Blood Journal, the constant research carried out on chronic myelogenous leukemia (CML) treatment resulted in the 2012 USFDA approval of three drugs for the treatment of CML: bosutinib, ponatinib, and omacetaxine. This is in addition to three others approved in the last decade: imatinib, dasatinib, and nilotinib.
In 2013, it was observed that three new drugs approved had been priced at high levels: ponatinib at US$ 138,000 per year, omacetaxine at US$ 28,000 for induction and US$ 14,000 per maintenance course, and bosutinib at US$ 118,000 per year. Cancer drug prices vary widely in different geographic regions. This supports the fact that drug prices reflect geopolitical and socioeconomic dynamics of the region unrelated to the cost of drug development. In the United States, prices represent the extreme end of high prices, a reflection of a “free market economy” and the notion that “one cannot put a price on a human life,” as well as a failure of government and insurers to more actively negotiate to price for anticancer and other pharmaceuticals, in contrast to practices in other parts of the world. Overall, the CML treatment market is growing slowly, but upcoming drug approvals are expected to boost the market.
